TNK2 and prostate carcinoma: These data revealed an unexpected modality of ICB resistance, namely, reactivation of pY-ACK1/pY18-CSK/pY505-LCK signalling, which further suggested that continued ICB treatment of prostate cancer patients may be counterproductive; however, ACK1 inhibitors are likely to have desirable effects.